This case report documents the response of a young, first-episode, neuroleptic naive male with severe catatonic schizophrenia to the novel antipsychotic, risperidone. Initial assessments included the Positive and Negative Syndrome Scales, Global Assessment of Function and the Extrapyramidal Symptom Rating Scale. These were repeated at discharge from hospital and during a 3.5 year outpatient follow-up. Neuroimaging (computed tomography, magnetic resonance imaging and single photon emission tomography) along with electro encephalogram and laboratory examinations were completed. Response to risperidone was prompt, dramatic and sustained over the follow-up period. Possible neurochemical brain mechanisms resulting in catatonia and the role of serotonin/dopamine antagonists such as risperidone are discussed. No other literature on the effect of risperidone in the treatment of severe catatonic schizophrenia in a first-episode patient has been reported.
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders (4th edn). American Psychiatric Association , Washington DC
2.
Bleuler E. (1950) Dementia praecox. International University Press, New York
3.
Bush G., Fink M., Petrides G., Dowling F., Francis A. (1996) Catatonia II: treatment with lorazepam and electroconvulsive therapy. Acta Psychiat Scand93: 137-143
4.
Chatterjee A., Chakos M., Koreen A., Geisler S., Sheitman B., Woerner M., Kane J.M., Alvir J., Lieberman JA (1995) Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenia patients . Am J Psychiat152:1724-1729
5.
Chouinard G., Ross-Chouinard A., Annable L., Jones B.D. (1980) The extrapyramidal symptom rating scale (abstract) . Can J Neurol Sci7: 233
6.
Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G.W. (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmac13: 25-40
7.
Cook E., Olson K., Pliskin N. (1996) Response of organic catatonia to risperidone. Archs Gen Psychiat53: 82-83
8.
Deakm J F W, Simpson M D C, Slater P., Hellewell J S E (1997) Familial and developmental abnormalities of frontal lobe function and neurochemistry in schizophrenia. J Psychopharmac11: 133-142
9.
Ebert D., Herbert F., Wolfgang K. (1992) Left temporal hypoperfusion in catatonic syndromes: a SPECT study. Psychiat Res: Neuroimag45: 239-241
10.
Fink M., Taylor M.A. (1991) Catatonia: a separate category in DSM-IVInteg Psychiat7: 2-10
11.
Guy W. ( 1976) ECDEU assessment manual for psychopharmacology (revised) . US Department of Health, Education, and Welfare publication ADM76-388, Rockville, MD
12.
Hawkins J., Archer K., Strakowski S. (1995) Somatic treatment of catatonia. Int J Psychiat Med25: 345-369
13.
Jeste D.V., Caligiuri M.P., Paulsen JS (1995) Risk of tardive dyskinesia in older patients. Archs Gen Psychiat52: 756-765
14.
Johnson J. (1993) Catatonia: the tension insanity. Br J Psychiat162: 733-738
15.
Kahlbaum K.L. (1874) Die Katatonie, oder das Spannungs Irresein, translation by Levij Y and Pridan T (1973). Johns Hopkins University Press, Baltimore, MD
16.
Kapur S., Remmgton G., Zipursky R., Wilson A., Houle S. (1995) The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci57: PL 103-107
17.
Kay S., Fishbein A., Opler L. (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull13: 261-275
18.
Kopala L., Fredrikson D., Good D., Honer W. (1996) Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone. Biol Psychiat39: 296-298
19.
Kopala L., Good K., Honer W. (1997) Extrapyramidal signs and symptoms in first episode schizophrenia: response to low dose risperidone. J Clin Psychopharmac17: 308-313
20.
Kopala L., Good K., Fredrikson D., Whitehorn D., Lazier L., Honer W. (1998) Risperidone in first-episode schizophrenia: improvement in symptoms and pre-existing extrapyramidal signs. Int J Psychiat Clin Pract2(Suppl.): S19-S25
21.
Leysen J.E., Gommeren W., Schotte A. (1996) Serotonin receptor subtypes: possible roles and implications in antipsychotic drug action. In Kane J M, Moller H J, Awouters F (eds), Serotoninin antipsychotic treatment: mechanisms and clinical practice. Marcel Dekker , New York, pp. 51-75
22.
London ED, Steven JG, Morgan MJ, Stephen RZ (1996) Neurobiology of drug abuse. In Fogel B S, Schiffer R B, Rao S M (eds), Neuropsychiatry. Williams & Wilkins, Baltimore, MD, pp. 653-657
23.
Marder S.R., Meibach R.C. (1994) Risperidone in the treatment of schizophrenia. Am J Psychiat151: 825-835
24.
Northoff G., Eckert J., Fritze J. (1997) Glutamatergic dysfunction in catatonia? Successful treatment of three acute kinetic catatonic patients with the NMDA antagonist amanadine. J Neurol Neurosurg Psychiat62: 404-406
25.
Osman A.A., Khurasani M.H. (1994) Lethal catatonia and neuroleptic malignant syndrome. A dopamine receptor shut-down hypothesis. Br J Psychiat165: 548-550
Rosebush P.I., Mazurek M.F. (1991) Drs Rosebush and Mazurek reply: a consideration of the mechanisms by which lorazepam might treat catatonia. J Clin Psychiat52: 187-188
28.
Rosebush P.I., Hildebrand A.M., Furlong B.G., Mazurek M.F. (1990) Catatonic syndrome in a general psychiatric inpatient population : frequency, clinical presentation, and response to lorazepam. J Clin Psychiat51: 357-362
29.
Rosebush P., Hildebrand A., Mazurek M. (1992) The treatment of catatonia: benzodiazepines or ECT? Am J Psychiat149:1279-1280
30.
Sackeim H.A., Stern Y. (1997) Neuropsychiatric aspects of memory and amnesia . In Yudofsky S C and Hales R E (eds), Textbook of neuropsychiatry , 3rd edn. American Psychiatric Press, Washington DC, pp. 501-518
31.
Satoh K., Suzuki T., Narits M., Ishikura S., Shibasaki M., Kato T., Takahashi S., Fukuyama H., Onishi H., Morita R. (1993) Regional cerebral blood flow in catatonic schizophrenia . Psychiat Res50: 203-216
32.
Taylor M.A. (1990) Catatonia: a review of the behavioural neurologic syndrome. Neuropsychiat Neuropsychol Behav Neurol3: 48-72
33.
Tsai G., Passam L., Slusher B., Carter R., Baer L., Kleinman J., Coyle J. (1995) Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Archs Gen Psychiat52: 829-836
34.
Ungvari G., Leung C., Wong M., Lau J. ( 1994) Benzodiazepines in the treatment of catatonic syndrome . Acta Psychiat Scand89: 285-288
35.
Wilcox J. (1991) Cerebellar atrophy and catatonia. Biol Psychiat29: 733-734
36.
Yassa R., Iskandar H., Lalinec M., Cleto L. (1990) Lorazepam as an adjunct in the treatment of catatonic states: an open clinical trial. J Clin Psychopharmac10: 66-68
